This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Delivered as Hybrid Event from 15-19 November 2021
Live In-Person Conference Delivered 15-17 NovemberSheraton Airport Brussels, Belgium

Marc Abrams, PhD
Vice President, Discovery Research at Dicerna Pharmaceuticals

Profile

As a Senior Research Director at Dicerna, I lead pipeline programs for specific targets/indications and support optimization of our RNAi technology platforms. I joined Dicerna in 2014 after 16 years at Merck and Co., Inc, where I held positions of increasing responsibility from Staff Biochemist through Associate Director. During that tenure, I worked as a biologist and pharmacologist on discovery programs across different modalities (small molecule and nucleic acid therapeutics) in oncology, virology and immunology. I hold a Ph.D. in Biochemistry from Thomas Jefferson University, where I studied under antisense pioneer Dr. Eric Wickstrom, and have authored or co-authored over 30 peer-reviewed publications.

Agenda Sessions

  • Discovery, Preclinical and Clinical Development of Oligonucleotides

    12:15
  • Progress on a Pipeline of Extrahepatic RNAi Therapeutics

    On Demand